ZA200901477B - Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors - Google Patents

Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors

Info

Publication number
ZA200901477B
ZA200901477B ZA200901477A ZA200901477A ZA200901477B ZA 200901477 B ZA200901477 B ZA 200901477B ZA 200901477 A ZA200901477 A ZA 200901477A ZA 200901477 A ZA200901477 A ZA 200901477A ZA 200901477 B ZA200901477 B ZA 200901477B
Authority
ZA
South Africa
Prior art keywords
pyrido
inhibitors
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
ZA200901477A
Other languages
English (en)
Inventor
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabeth Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200901477B publication Critical patent/ZA200901477B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
ZA200901477A 2006-09-15 2009-03-02 Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors ZA200901477B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
ZA200901477B true ZA200901477B (en) 2010-07-28

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200901477A ZA200901477B (en) 2006-09-15 2009-03-02 Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors

Country Status (41)

Country Link
US (3) US7696213B2 (de)
EP (1) EP2074122B9 (de)
JP (1) JP4718637B2 (de)
KR (1) KR101099926B1 (de)
CN (1) CN101573358B (de)
AP (1) AP2710A (de)
AR (1) AR062785A1 (de)
AT (1) ATE514695T1 (de)
AU (1) AU2007297212B8 (de)
BR (1) BRPI0716749B8 (de)
CA (1) CA2663401C (de)
CL (1) CL2007002682A1 (de)
CR (1) CR10662A (de)
CU (1) CU23783B7 (de)
CY (1) CY1111911T1 (de)
DK (1) DK2074122T5 (de)
DO (1) DOP2009000039A (de)
EA (1) EA016388B1 (de)
ES (1) ES2366489T3 (de)
GE (1) GEP20115306B (de)
GT (1) GT200700077A (de)
HN (1) HN2007000267A (de)
HR (1) HRP20110621T2 (de)
IL (1) IL197243A (de)
MA (1) MA30709B1 (de)
ME (1) MEP8009A (de)
MX (1) MX2009002927A (de)
MY (1) MY146420A (de)
NI (1) NI200900032A (de)
NO (1) NO342357B1 (de)
NZ (1) NZ575167A (de)
PE (1) PE20080670A1 (de)
PL (1) PL2074122T3 (de)
PT (1) PT2074122E (de)
RS (2) RS51927B (de)
SI (1) SI2074122T1 (de)
TN (1) TN2009000085A1 (de)
TW (1) TWI334353B (de)
UY (1) UY30588A1 (de)
WO (1) WO2008032162A1 (de)
ZA (1) ZA200901477B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007297212B8 (en) * 2006-09-15 2011-04-28 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
EA020022B1 (ru) * 2007-04-10 2014-08-29 Экселиксис, Инк. Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
WO2008127712A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
CA2729914A1 (en) * 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2439009T3 (es) * 2008-08-20 2014-01-21 Merck Sharp & Dohme Corp. Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP2012504628A (ja) * 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド ＰＩ３ＫαおよびｍＴＯＲのピリドピリミジノン阻害剤
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CA2846454A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
WO2016055907A1 (en) 2014-10-10 2016-04-14 Pfizer Inc. Synergistic auristatin combinations
BR112017025398A2 (pt) 2015-06-04 2018-08-07 Pfizer Inc. formas de dosagem sólidas de palbociclib
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2019519593A (ja) 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
BR112019002610A2 (pt) 2016-08-15 2019-07-02 Pfizer piridopirimidinonas inibidoras de cdk2/4/6
CA3045041A1 (en) * 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
AU2019413683B2 (en) * 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140053A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
JP2024542205A (ja) * 2021-11-18 2024-11-13 オンコノヴァ セラピューティクス， インコーポレイテッド がんを処置するための方法および組成物
PE20250609A1 (es) 2021-12-03 2025-02-26 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
CN121443294A (zh) 2023-06-08 2026-01-30 林伯士瓦吉特公司 Wrn抑制剂
US20250206738A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
MX9702245A (es) 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
CZ20022521A3 (cs) 2000-01-27 2003-02-12 Warner-Lambert Company Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění
EE200200506A (et) 2000-03-06 2004-02-16 Warner-Lambert Company 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
WO2002068419A1 (en) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
ATE314370T1 (de) 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
CN1835951B (zh) 2003-07-11 2010-06-02 沃尼尔·朗伯有限责任公司 选择性cdk4抑制剂的羟乙基磺酸盐
JP2006528193A (ja) 2003-07-22 2006-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼの阻害剤としてのキノリノン誘導体
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2553785C (en) 2004-02-14 2011-02-08 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007523151A (ja) 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
DE602005002562T2 (de) * 2004-05-04 2008-01-31 Warner-Lambert Company Llc Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
BRPI0511065A (pt) 2004-06-04 2007-12-26 Pfizer Prod Inc método para tratar crescimento de célula anormal
JP2008510770A (ja) 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
AU2005301957B2 (en) 2004-11-03 2012-02-23 Department Of Health And Human Services Novobiocin analogues as anticancer agents
EP1828186A1 (de) 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyridopyrimidinone, dihydropyrimidopyrimidinone und pteridinone, die sich als raf-kinase-inhibitoren eignen
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
EP1872922A1 (de) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Verfahren und Vorrichtung zur Herstellung eines Kunststoff-Gegenstandes
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
AU2007297212B8 (en) 2006-09-15 2011-04-28 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
KR20090130051A (ko) * 2007-03-14 2009-12-17 엑셀리시스, 인코포레이티드 헤지호그 경로의 억제제
WO2008127712A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
JP2012504628A (ja) 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド ＰＩ３ＫαおよびｍＴＯＲのピリドピリミジノン阻害剤
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations

Also Published As

Publication number Publication date
CA2663401C (en) 2011-07-12
US8273755B2 (en) 2012-09-25
PT2074122E (pt) 2011-08-24
US20100137279A1 (en) 2010-06-03
HRP20110621T2 (hr) 2013-12-06
CN101573358B (zh) 2012-05-30
US8633204B2 (en) 2014-01-21
IL197243A0 (en) 2009-12-24
WO2008032162A1 (en) 2008-03-20
CU20090040A7 (es) 2011-07-11
EP2074122A1 (de) 2009-07-01
EA200970207A1 (ru) 2009-08-28
KR101099926B1 (ko) 2011-12-28
BRPI0716749A2 (pt) 2014-02-18
MX2009002927A (es) 2009-03-31
RS20090104A (sr) 2010-06-30
CR10662A (es) 2009-04-17
BRPI0716749B1 (pt) 2020-10-06
DK2074122T3 (da) 2011-08-15
HRP20110621T1 (hr) 2011-09-30
AP2710A (en) 2013-07-30
GEP20115306B (de) 2011-10-10
KR20090040389A (ko) 2009-04-23
MEP8009A (en) 2011-12-20
HK1138589A1 (en) 2010-08-27
CL2007002682A1 (es) 2008-04-04
CA2663401A1 (en) 2008-03-20
ES2366489T9 (es) 2013-12-27
ATE514695T1 (de) 2011-07-15
AU2007297212B2 (en) 2011-04-14
NZ575167A (en) 2010-10-29
NO342357B1 (no) 2018-05-14
CU23783B7 (es) 2012-02-15
TWI334353B (en) 2010-12-11
NO20091141L (no) 2009-03-31
EP2074122B9 (de) 2013-09-11
RS51927B (sr) 2012-02-29
JP4718637B2 (ja) 2011-07-06
AU2007297212B8 (en) 2011-04-28
GT200700077A (es) 2009-08-03
US20080090801A1 (en) 2008-04-17
AP2009004790A0 (en) 2009-04-30
AU2007297212A1 (en) 2008-03-20
AR062785A1 (es) 2008-12-03
EA016388B1 (ru) 2012-04-30
CN101573358A (zh) 2009-11-04
EP2074122B1 (de) 2011-06-29
PL2074122T3 (pl) 2011-10-31
PE20080670A1 (es) 2008-06-14
DOP2009000039A (es) 2015-12-15
MY146420A (en) 2012-08-15
JP2010503653A (ja) 2010-02-04
UY30588A1 (es) 2008-05-02
DK2074122T5 (da) 2014-03-17
HN2007000267A (es) 2011-02-25
IL197243A (en) 2013-07-31
SI2074122T1 (sl) 2011-10-28
US20120309775A1 (en) 2012-12-06
US7696213B2 (en) 2010-04-13
BRPI0716749B8 (pt) 2021-05-25
ES2366489T3 (es) 2011-10-20
WO2008032162A8 (en) 2009-03-26
TN2009000085A1 (fr) 2010-08-19
CY1111911T1 (el) 2015-11-04
NI200900032A (es) 2010-05-14
TW200820972A (en) 2008-05-16
MA30709B1 (fr) 2009-09-01

Similar Documents

Publication Publication Date Title
IL197243A0 (en) Pyrido (2,3-d)pyrimidinone compounds and their use as pi3 inhibitors
IL210821A0 (en) Pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
IL198509A0 (en) Azaindole derivatives, compositions containing the same and uses thereof
IL201836A0 (en) Pyrrolopyridine derivatives and their use as bace inhibitors
ZA201004524B (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
PL2004654T3 (pl) Pochodne pirazolopirymidyny do stosowania jako antagonisty kinazy
EP1993539A4 (de) Thiazolone als pi3-kinasehemmer
IL210822A0 (en) Tri-cyclic pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
IL197231A0 (en) Pyrimidines derivatives and their use as kinase inhibitors
ZA201005338B (en) Pyrrolo[2,3-d]pyridines and use thereof as tyrosine kinase inhibitors
IL198250A0 (en) Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
IL186881A0 (en) Pyrido [2, 3 - d] pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
LT2050749T (lt) Pirimidino darinys, kaip pi3k inhibitorius, ir jo panaudojimas
EP2217590A4 (de) Pyridopyrimidinderivate als pi3-kinase-inhibitoren
HRP20130660T1 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
EP1993535A4 (de) Thiazolone als pi3-kinasehemmer
EP2061470A4 (de) Haloalkyl-substituierte pyrimidinon-derivate
IL210074A0 (en) Compositions with and process for methylmorpholin-substituted pyrido[2,3-d]pyrimidines
SI2004654T1 (sl) Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
EP1993536A4 (de) Thiazolone als pi3-kinasehemmer
EP1993537A4 (de) Thiazolone als pi3-kinasehemmer
EP1996191A4 (de) Thiazolone als pi3-kinasehemmer